This is a working overview of pituitary axis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-16 and is reviewed periodically as new material appears.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
== Literature == Hofmann K, Lucas RA, SAX SM (1952). "The chemical nature of the fatty acids of Lactobacillus arabinosus". J Biol Chem. 195 (2): 473–85. doi:10.1016/S0021-9258(18)55754-9. PMID 14946156.{{cite journal}}: CS1 maint: multiple names: authors list (link) Dennis W. Grogan, John. E. Cronan, Jr. (1997), "Cyclopropane ring formation in membrane lipids of bacteria", Microbiology and Molecular Biology Reviews, vol. 61, no. 4, pp. 429–441, Bibcode:1997MMBR...61..429G, doi:10.1128/mmbr.61.4.429-441.1997, PMC 232619, PMID 9409147{{citation}}: CS1 maint: multiple names: authors list (link)
=== Prehistory === The first Aleutian occupants are thought to have arrived following Beringian migrations. Where the mainland of Alaska is thought to have been occupied before 15,000 years before present, the Aleutians were likely first occupied approximately 9,000 before present with the earliest archaeological sites found dating to that period, there is a possibility of an earlier occupation as early as 14,000 years ago as melting glaciers exposed the western shorelines of the Alaska Peninsula. The migration of the early Unangax̂ across the island chain would take thousands of years, beginning with the eastern islands, sites on Unalaska have been found which date to 9000 years before present. In the central islands, sites on Adak Island begin appearing approximately 6000 years before present. The western islands were the last settled, with sites beginning to appear 2,500 years before present. Within longest archaeological record in the Eastern Aleutians; the archaeological periods noted by archeologists Knecht and Davis are broken into Anangula phase (9000-7000 BP), Late Anangula (7000-4000 BP), the Margaret Bay Phase (4000-3000 BP), Amaknak Phase (3000-1000 BP), and the Late Aleutian Phase (1000-200 BP). The final three phases have also been noted as the Aleutian tradition. People living in the Aleutian Islands developed rich culture intimately tied to marine resources.
== Personal life == Paetongtarn's nickname is Ung Ing (Thai: อุ๊งอิ๊ง), which is sometimes shortened to Ing. She is married to Pitaka Suksawat, a Thai businessman who is the Deputy Chief Investment Officer of Rende Development Co., Ltd., and a board member of the Thaicom Foundation. Pitak and Paetongtarn have one daughter who was born on 10 January 2021, and one son, who was born on 1 May 2023. In her asset declaration for 2024, she revealed a collection of 217 luxury handbags and 75 luxury watches, with a total net worth of over US$400 million.
Sources: en.wikipedia.org
No chromosome translocations, chimeric genes, or fusion proteins have been described in BIA-ALCL although the neoplastic cells in the disease have been described to have gene copy number variations involving gains in gene copies on the p arm of chromosome 19 and losses of gene copies in the p arms of chromosome 10 and 1. The neoplastic cells in BIA-ALCL show mutations of the STAT3 gene in 64% of cases and reports of mutations in JAK1, JAK3, DNMT3A, and TP53 genes. The development of BIA-ALCL, it has often been suggested, may be at least in part a T-cell-induced, inflammation-driven cancer response to the implant.
AMS counts the atoms of 14C and 12C in a given sample, determining the 14C/12C ratio directly. The sample, often in the form of graphite, is made to emit C− ions (carbon atoms with a single negative charge), which are injected into an accelerator. The ions are accelerated and passed through a stripper, which removes several electrons so that the ions emerge with a positive charge. The ions, which may have from 1 to 4 positive charges (C+ to C4+), depending on the accelerator design, are then passed through a magnet that curves their path; the heavier ions are curved less than the lighter ones, so the different isotopes emerge as separate streams of ions. A particle detector then records the number of ions detected in the 14C stream, but since the volume of 12C (and 13C, needed for calibration) is too great for individual ion detection, counts are determined by measuring the electric current created in a Faraday cup. The large positive charge induced by the stripper forces molecules such as 13CH, which has a weight close enough to 14C to interfere with the measurements, to dissociate, so they are not detected. Most AMS machines also measure the sample's δ13C, for use in calculating the sample's radiocarbon age. The use of AMS, as opposed to simpler forms of mass spectrometry, is necessary because of the need to distinguish the carbon isotopes from other atoms or molecules that are very close in mass, such as 14N and 13CH. As with beta counting, both blank samples and standard samples are used.
=== Long-acting === Long-acting insulin analogues are designed to provide continuous basal insulin coverage for up to 24 hours, with the exception of ultra-long-acting analogues, which work for up to a week. These include insulin glargine, insulin detemir, insulin degludec, and insulin icodec, which have been modified through amino acid substitutions and fatty acid conjugation to alter their subcutaneous absorption and extend their duration of action. A key feature of long-acting insulin analogues is reversible albumin binding and di-hexamer formation, which slow insulin dissociation and provide a more stable pharmacokinetic and pharmacodynamic profile, reducing glycemic fluctuations and nocturnal hypoglycemia. Insulin glargine (100 U/mL), first approved by the US Food and Drug Administration (FDA) in 2000 and marketed as Lantus, forms zinc-mediated hexamer aggregates after injection, resulting in a slow insulin release. In 2015, a higher-concentration formulation (300 U/mL), marketed as Toujeo, was introduced, offering up to 36-hour coverage and a lower risk of nocturnal hypoglycemia. Insulin detemir, approved in 2005 as Levemir, features a C14 fatty acid modification at lysine B29, promoting di-hexamer formation and albumin binding for an extended duration. While effective, insulin detemir often requires twice-daily dosing for optimal glycemic control.
On 9 August, Bildt compared Russia's reason for going to war with Georgia to Adolf Hitler's actions, "No state has the right to intervene militarily in the territory of another state simply because there are individuals there with a passport issued by that state or who are nationals of the state. Attempts to apply such a doctrine have plunged Europe into war in the past... And we have reason to remember how Hitler used this very doctrine little more than half a century ago to undermine and attack substantial parts of central Europe". A UN Security Council diplomat said: "Strategically, the Russians have been sending signals that they really wanted to flex their muscles, and they're upset about Kosovo." On 10 August, Russian human rights activist Sergei Kovalev called on the international community to condemn Russia's actions since Russia launched an aggression against Georgia on the pretext of defence of Russian citizens. The statement said that Russia was no longer a peacekeeper, but a party to the conflict. The statement was supported by Lev Ponomaryov and other Russian human rights activists. On 11 August, Ronald Asmus and Richard Holbrooke wrote that Georgia acted in response to provocation by Russian-backed separatists and Georgia did not want the war because it was already using soft power to attain its goals in South Ossetia.
Sources: en.wikipedia.org
Further, chemical biology employs biological systems to create non-natural hybrids between biomolecules and synthetic devices (for example, emptied viral capsids that can deliver gene therapy or drug molecules).
Temgicoluril is used in Latvia and Russia, as a pharmaceutical drug to treat anxiety and to prevent or reduce anxiety, unrest, fear, internal emotional tension and irritability, reduce neuroses and neurotic disorders, heartburns of non-coronary heart disease origin. These effects are not accompanied with relaxation of muscle tone and impaired coordination of movement, suppression of mental and physical activity, so the drug can be used without interruption of work or school. Temgicoluril does not have a direct effect on sleep, however, it enhances the effectiveness of sleep medicines and normalizes the course of disturbed sleep. Temgicoluril alleviates or eliminates the manifestations of nicotine dependence that occur after smoking cessation. Although temgicoluril does not cause mood swings or euphoria, habituation, nor addiction, withdrawal syndrome has been observed.
=== Names === Polatuzumab vedotin is the international nonproprietary name and the United States Adopted Name. Genentech included "Pol" in the generic and trade names in honor of Andy Polson, one of the scientists who discovered the drug.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.